Loading data for XBI — first visit, this takes a few seconds.

State Street SPDR S&P Biotech ETF (XBI)

NYSEArca: XBI · Real-Time Price · USD

163.40

+0.90 (0.55%)

At close: Sep 01, 2026, 8:00 PM

Alert

The price, the headline numbers and the latest news, in one place.

No data available

Bid	163.41
Market Cap	n/a
Revenue (ttm)	n/a
Net Income (ttm)	n/a
	0.00
	n/a
	n/a
	n/a
P/B (ttm)	0.00
P/S (ttm)	0.00
Earnings Date	n/a

Ask	163.32
Volume	8,441,181
Avg. Volume (20D)	9,075,341
Open	161.75
Previous Close	162.50
Day's Range	161.16 - 163.44
52-Week Range	91.10 - 169.89
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About XBI

In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI")....

[Read more]

Industry n/a

Sector n/a

IPO Date Feb 6, 2006

Employees n/a

Stock Exchange NYSEArca

Ticker Symbol XBI

Full Company Profile

Financial Performance

In undefined, State Street SPDR S&P Biotech ETF's revenue was n/a, an increase of undefined% compared to the previous year's n/a. Earnings were n/a, an increase of undefined%.

Financial Statements

Earnings Surprise

State Street SPDR S&P Biotech ETF has released their quarterly earnings on Invalid Date:

Revenue of n/a misses estimates by $0, with NaN% YoY growth.
EPS of misses estimates by , with NaN% YoY growth.

Why Price Moved

News

1 week ago · Barchart

Regeneron Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish?

Regeneron Pharmaceuticals has comfortably outperformed the S&P 500 over the past year, and Wall Street remains reasonably bullish on the company’s long-term growth prospects.

1 week ago · 24/7 Wall St.

Moderna Rallies 11%, BioNTech Ticks Up: Is the mRNA Trade Down to One Name?

Moderna just posted an 11% surge with zero news behind it, while its longtime mRNA peer BioNTech can barely keep pace with the broader biotech sector. Something broke between these two names, and figu...

1 week ago · Investor's Business Daily

Analysts See Drastic Change For This Particular Part Of Healthcare

The biotech fund is one of two ETFs in IBD Leaderboard. The S&P 500 Biotech index gapped up to nearly an all-time high last Wednesday, a bullish day for the industry. While Moderna shares have remai...

1 week ago · Barchart

BioNTech Moved Higher as the Broader Biotech Sector Hit a Post-Pandemic Peak, but BNTX Stock Needs Stronger Fundamentals to Keep Climbing

BioNTech shares moved higher as the broader biotech sector reached a post-pandemic peak, lifted by positive late-stage cancer vaccine data from peers rather than new clinical results of its own.

1 week ago · Zacks

Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)?

Sector ETF report for XBI

Page 1 of 2

State Street SPDR S&P Biotech ETF (XBI)